Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Breakthrough Technology for a Brighter Future PowerPoint Presentation
Download Presentation
Breakthrough Technology for a Brighter Future

Breakthrough Technology for a Brighter Future

190 Vues Download Presentation
Télécharger la présentation

Breakthrough Technology for a Brighter Future

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Breakthrough Technology for a Brighter Future

  2. Oramed Pharmaceuticals OTC Bulletin Board: ORMP Company with oral drug delivery platform Based on over 25 years of medical research at Hadassah University Medical Center - Jerusalem World leading scientific team Experienced management team Diverse product pipeline Oral Insulin (ORMD 0801): Flag Ship Product

  3. Oramed’s Delivery Platform Normal digestion involves degradation of proteins/peptides Breakdown by acidic pH of stomach + digestive enzymes Oramed’s patent-pending technology platform is designed to protect and ferry proteins to target in its intact and biologically active form. enhances a protein's absorption through the gut wall into the bloodstream

  4. Oral insulin is the only delivery system that mimics the biological and physiological processes With an oral delivery system, insulin can become an earlier treatment modality with higher compliance Oral Insulin

  5. History of Development – Oral Insulin – ORMD 0801 Phase 1A trials August 2007 Successful pre-clinical results April 2006 Phase 1B trials March 2008 IND filing Expected 4th Quarter 2009 Company established March 2006 Swiss Caps agreement October 2006 IRB Approval Phase 2B (South-Africa) September 2008 2007 2009 Phase 2B trials May 2009 Phase 2AAugust 2008 2008

  6. Oramed’s Product Pipeline • Oral Insulin • Phase 2a trials completed August 2008 • Phase 2b trials began in May 2009 • Insulin Suppository • Successful pre-clinical trials • Phase 1 trials in South Africa • GLP1-Analog • Pre-clinical trials – Completed 2008 • Phase 1 trials expected in second half of 2009 • Platform drug delivery technology for a variety of peptides

  7. Competitive Landscape Oral Insulin Capsule: • Diabetology (UK, Phase 2) • Emisphere Technologies (US, Phase 2) • Biocon (India)

  8. Scientific Advisory Board Nir Brazilai, MD Director for the institute of aging research. Member of Diabetes Research Center, Albert Einstein University college of Medicine. Prof. Ele Ferrannini Prof. of Internal Medicine, University of Pisa school of Medicine. Professor of Medicine, Diabetes Unit Texas Health science center. Prof. Avram Herskho, MD, PhD Distinguished Professor in the Biochemistry unit in the B. Rappaport Facility of Medicine in the Technion in Haifa. Nobel Prize Laureate in Chemistry (2004) for the discovery of Ubiquitin- mediated protein degradation. Derek LeRoith, MD Professor of Medicine and Chief of Endocrinology, Diabetes and Bone Disease unit, Mount Sinai NY.

  9. Oramed in the news Oramed’s Oral Insulin Capsule listed as one of the five most promising drugs entering Phase 1 Trials by Thompson Pharma Chosen from hundreds of companies to represent Israel at the President’s Conference celebrating Israel’s 60th birthday (2008)

  10. Summary Patent pending technology platform for oral delivery of medications currently delivered via injection In the pipeline: Oral and rectal delivery of Insulin GLP1-Analog Strong management team, leading scientific team and clear proof of concept